NEW YORK (GenomeWeb) – The Scripps Research Institute (TSRI) announced today that it has partnered with Pfizer to develop a novel chemical synthesis technology for creating next-generation DNA-encoded libraries (DELs).
Under the terms of the deal, Pfizer will pay an undisclosed fee to gain access to a chemical synthesis technology developed at TSRI. The two will adapt this technology for use in creating DELs, and choose to expand their joint research to include other technologies enabling DEL-based drug discovery.
Additional terms were not disclosed.
"We hope that this new collaboration will contribute to the creation of novel chemistries that can be used by Pfizer to prepare unique libraries for screening which, together with our parallel medicinal chemistry expertise, will have the potential to help us accelerate the discovery of new medicines for patients," Tony Wood, senior vice president and head of medicinal sciences at Pfizer, said in a statement.